Ionova Completes $100 Million Round for Targeted and Immuno Therapies
August 30, 2021 at 05:39 AM EDT
Shenzhen Ionova Life Science completed a $100 million financing to support its novel targeted and immuno therapies for cancer. Its research arm, Touchstone Translational Research Institute, uses its biology-driven drug discovery platforms for new candidates while also collaborating with academia and biopharmas to translate basic biomedical research discoveries into novel therapies. Based on insights into the tumor microenvironment and immunoregulation, the company applies its "immunotherapy + targeted therapy" strategy. The financing was led by Tsing Song Capital, Shenzhen Capital Group Company and Greater Bay Area Homeland Development Fund. More details.... Share this with colleagues: // //